Home / Medical Care in China / Hematology / Primary immune thrombocytopenic purpura

Medical Care in China

Primary immune thrombocytopenic purpura
Treatment in China

Provide a clear and complete coordinated pathway from expert assessment to treatment and rehabilitation.

Get a Care Plan and Cost Estimate

The coverage of blood diseases is broadincluding anemia, leukemia, lymphoma, and myeloma.

Precise blood diagnosisclarifies the condition through bone marrow, molecular and genetic examinations.

Cell therapy selectionCAR-T and other therapies are evaluated for eligible patients.

Transplantation therapy supportcovers hematopoietic stem cell transplantation and related management.

Condition Guide

About Primary immune thrombocytopenic purpura

Understand the condition, common triggers and treatment options that may require specialist assessment.

Disease Introduction

Primary immune thrombocytopenic purpura (ITP) is a hemorrhagic disease caused by increased platelet destruction and insufficient platelet production mediated by the autoimmune system. Symptoms include petechiae and ecchymoses on the skin, bleeding gums, and nosebleeds; in severe cases, internal bleeding may occur. It is more common in adults as a chronic condition, while in children it is more often acute. The treatment goal is to raise the platelet count to a safe level and reduce the risk of bleeding, and second-line treatment options are becoming increasingly available.

Cutting-edge high-precision diagnostic and treatment technologies

TPO-RA first-line treatment : TPO receptor agonists such as eltrombopag, romilastine, avatrombopag, and hetrombopag have become the first-line or second-line treatment for adult ITP, with convenient oral administration, rapid onset of action, and high response rate.
Oral BTK inhibitors : In August 2025, the FDA approved the first oral BTK inhibitor, rilzabrutinib, for chronic/persistent ITP. It modulates the disease by regulating Fc receptor and B cell receptor signaling. The LUNA 3 study showed a durable platelet response.
Syk pathway inhibition : Fortenatinib (a Syk inhibitor) provides a new oral mechanism for chronic ITP with multiple line failures, and complements the mechanisms of TPO-RA and rituximab.
Domestically produced new drugs for children : In September 2026, the NMPA approved hetrombopag for chronic ITP in children aged 6 years and older, providing pediatric patients with the first domestically produced oral TPO-RA.
Guideline Update Recommendations : The ASH 2026 guidelines recommend that dexamethasone and TPO-RA be combined for treatment-naïve patients, and strongly recommend TPO receptor agonists for second-line treatment, and recommend management of switching between TPO-RAs.

Care Overview

Primary immune thrombocytopenic purpura Treatment in China

The medical team will develop a personalized protocol based on the pathology type, stage, genetic test, previous treatment history, and the patient's physical condition.

1. Initial treatment stratification : For adults, glucocorticoids can be used alone or in combination with TPO-RA to rapidly increase platelet count; intravenous immunoglobulin should be added for patients with acute and severe bleeding.
2. Second-line TPO-RA : For patients who do not respond well to first-line treatment, oral or subcutaneous TPO-RA (eltrombopag, romilastine, avatrombopag, hetrombopag) is preferred, with individualized titration and slow tapering.
3. Immunomodulatory therapy : Rituximab, fortenatinib, or the BTK inhibitor rilzabrutinib are suitable for patients who are not suitable for or have insufficient efficacy in TPO-RA, achieving immunomodulation and disease modification.
4. Comprehensive management of refractory patients : evaluate splenectomy, combined immunosuppression, or clinical trials of new drugs for patients who have failed multiple lines of treatment; conduct a comprehensive assessment of bleeding risk and infection prevention before splenectomy.
5. Prevention and control of bleeding throughout the treatment process: During treatment, platelet count and bleeding symptoms should be monitored regularly, anticoagulants and strenuous activity should be avoided, and platelet component transfusion and local hemostasis should be performed when necessary.

1. Controllable bleeding risk : TPO-RA and other drugs can rapidly increase platelet count to a safe level, significantly reducing the risk of bleeding from the skin, mucous membranes and internal organs.
2. Convenient oral administration and adherence : Eltrombopag, Hetrombopag, Avatrombopag, and BTK inhibitors are all taken orally, reducing the burden of hospitalization and injections when taken at home.
3. A New Chapter in Disease Modification : BTK inhibitors and Syk inhibitors intervene at the source of immune disorders, and some patients can achieve sustained remission after discontinuing medication.
4. Expanded benefits for children : The domestically produced oral TPO-RA has been approved for pediatric indications, and the treatment of ITP in children has shifted from injection to oral administration, improving both compliance and accessibility.
5. Ample step-by-step treatment options : From glucocorticoids to TPO-RA, immunomodulation, splenectomy and clinical trials, multiple lines of treatment options ensure that patients have medication options throughout their treatment journey.

Network of partner hospitals

Recommended Hospitals

Selected leading medical centers with strong specialties and international patient services.

Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Beijing · Partner Hospital

Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Hematology

The institute is the supporting unit of the National Clinical Research Center for Hematological Diseases, the National Stem Cell Engineering Technology Research Center, and the Stem Cell Medicine Center of the Chinese Academy of Medical Sciences. It is also the executive department of the World Federation of Hemophilia (China), the supporting unit of the National Hemophilia Case Information Management Center, and is leading the establishment of the National Quality Control Center for Hematology. For many consecutive years, it has ranked first in the Fudan University ranking of hematology disciplines, and its CAR-T cell therapy center for hematological diseases ranks second in the country.

Year Founded: 1957
Beds: 1540

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai · Partner Hospital

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

OncologyHematologyGastroenterologyUrologyInternal MedicineSurgeryOrthopedics

Ruijin Hospital consistently ranks among the top four hospitals in China according to the comprehensive hospital rankings released by the Fudan University Hospital Management Institute. It is a national medical center construction unit and possesses national-level platforms such as the National Clinical Research Center for Metabolic Diseases and the National Clinical Research Center for Hematological Diseases. The hospital currently has four key disciplines designated by the Ministry of Education (Hematology, Endocrinology and Metabolic Diseases, Cardiology, and Neurology), 22 national key clinical specialties, and one national key laboratory for medical genomics. The hospital has been awarded the title of National Civilized Unit four times consecutively and has received honors such as the National May 1st Labor Medal and the National Advanced Collective of the Health System. It is also a national demonstration unit for integrated traditional Chinese and Western medicine.

Year Founded: 1907
Beds: 5100

Southern Medical University Southern Hospital

Guangzhou · Partner Hospital

Southern Medical University Southern Hospital

Organ TransplantHematologyInternal MedicineCosmetic Surgery

The hospital is a national regional trauma medical center jointly constructed by the provincial and national governments, a national project unit for improving the diagnosis and treatment capabilities of difficult and complex diseases (tumors), a national regional TCM (rheumatology) treatment center, a national emergency medical rescue base, and one of the first key construction units in Guangdong Province's "Peak Climbing Plan" for high-level hospitals. It boasts 5 national key disciplines, 17 national key clinical specialties, and 4 national key clinical specialty construction projects. In the 2023 national public hospital performance evaluation, it ranked in the A+ category. In authoritative domestic hospital rankings, the hospital consistently ranks among the top 15 to 20 comprehensive hospitals nationwide, with more than ten specialties, including nephrology, infectious diseases, plastic surgery, hematology, pathology, and gastroenterology, ranking in the top ten or receiving nominations.

Year Founded: 1941
Beds: 2225

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan · Partner Hospital

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

HematologyCardio-CerebrovascularUrology

The hospital ranks 9th nationwide in the Fudan University China Hospital Specialty Ranking, making it one of the strongest hospitals in Central China. Its specialties, including heart transplantation, hematology, ultrasound, nuclear medicine, anesthesiology, and cardiovascular surgery, are among the top in the country. In particular, its nuclear medicine department has consistently ranked among the top two in Fudan University's specialty rankings for many years, and its heart transplant volume has ranked first in the country for many consecutive years. The hospital is a national drug clinical trial institution and a national stem cell clinical research institution, boasting strong research capabilities.

Year Founded: 1866
Beds: 6000

Leading Specialists

Trusted Expertise Across Leading Specialties

Feng Ru

Professor, Chief Physician, Doctoral Supervisor, Deputy Director of Department, Head of Lymphoma Subspecialty

Hematology

-Research areas : pathogenesis, diagnosis and treatment of lymphoma and multiple myeloma, targeted immunotherapy, and leukemia. - Cutting-edge technologies: Dynamic monitoring of MRD for lymphoma and myeloma, and clinical research on new drugs for relapsed and refractory lymphomas. - Areas of expertise: Hodgkin's/non-Hodgkin's lymphoma, multiple myeloma, plasma cell diseases, lymphoma, leukemia. - Academic Highlights & Value: Visiting scholar experience in the United States and Japan; presided over multip

Affiliated Hospital Southern Medical University Southern Hospital

Sun Jing

Professor, Chief Physician, Doctoral Supervisor, Deputy Director of Department, Director of Hemophilia Center

Hematology

-Research areas : Hematopoietic stem cell transplantation, bleeding disorders, and hemophilia diagnosis and treatment - Cutting-edge technologies: unrelated hematopoietic stem cell transplantation, hemophilia inhibitor immune tolerance induction program/comprehensive diagnosis and treatment of hemophilia and inhibitor management (the largest hemophilia center in South China), prevention and treatment of transplant complications. - Areas of expertise: Hemophilia, von Willebrand disease, platelet disorders,

Affiliated Hospital Southern Medical University Southern Hospital

Zhang Xiaobing

Researcher, doctoral supervisor, head of the cell gene transformation platform

Hematology

Research areas : gene editing, CAR vector design, iPSC, LNP delivery technology; Cutting-edge technologies: CRISPR gene editing CAR cells, GMP construction of lentiviral vectors; Areas of expertise: CAR vector development, gene therapy; Academic highlights: National high-level talent, multiple cell therapy invention patents; Core value: Supporting the research and clinical translation of underlying vector technologies for CAR-T and gene therapy.

Affiliated Hospital Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Zhao Weili

Chief Physician, Level 2 Professor, Doctoral Supervisor, Director of Shanghai Institute of Hematology, Vice President of Ruijin Hospital

Hematology

-Research areas : lymphoma immunotherapy, CAR-T cell therapy clinical research, and real-world CAR-T studies in Asian populations. - Cutting-edge technologies: CAR-T stratified treatment system for relapsed and refractory large B-cell lymphoma; CAR-T adverse reaction MDT management model. - Areas of expertise: Diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, and other B-cell non-Hodgkin lymphomas. - Academic Highlights: Led a multicenter real-world study of CAR-T th

Affiliated Hospital Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Liu Qifa

Level 2 Professor, Chief Physician, Doctoral Supervisor, Academic Leader, Director of the Institute of Hematology

Hematology

Research areas : Molecular pathogenesis of leukemia, hematopoietic stem cell transplantation, tumor immunotherapy, and prevention and treatment of infections in immunocompromised hosts. - Cutting-edge technologies: Haploidentical hematopoietic stem cell transplantation; MICM precision stratification therapy for leukemia; precision stratification therapy for acute leukemia (rewriting the NCCN/ELN guidelines); combined haploidentical and umbilical cord blood transplantation (Lancet RCT); MSC prevention of G

Affiliated Hospital Southern Medical University Southern Hospital

Li Junmin

Head of Hematology

Hematology

Research areas : hematologic malignancies and hematologic immune diseases; construction of CAR-T clinical research system. Cutting-edge technology: creation of translational medicine wards and CAR-T clinical trial screening system. Specializes in treating: acute myeloid leukemia, multiple myeloma, and lymphoma. Academic Highlights: Led the establishment of China's first translational medicine ward in hematology; emphasized that CAR-T "is a novel immunotherapy that acts on the tumor microenvironment and ha

Affiliated Hospital Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Patient Stories

See the Next Step Through Patient Journeys

Lower Extremity Arteriosclerosis Obliterans - A Masterpiece for Unblocking the

CASE 01

PATIENT JOURNEY

Lower Extremity Arteriosclerosis Obliterans - A Masterpiece for Unblocking the "Silent Killer"

HematologyCardio-Cerebrovascular

Patient records Name: Carlos Silva Age: 70 Nationality: Brazil (São Paulo) Diagnosis: Lower extremity arteriosclerosis obliterans (Rutherford grade 4, long segment occlusion of the left superficial femoral artery, rest pain) Treatment Hospital: Department of Vascular Surgery, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Mr. Carlos is a passionate samba dancer who, even in his seventies, still enjoys swaying to the music on the streets of Rio. However, for the past six mo

View case details →

Lymphoma : While CAR-T therapy is prohibitively expensive and has long waiting times in the West: An Australian patient found an accessible

CASE 02

PATIENT JOURNEY

Lymphoma : While CAR-T therapy is prohibitively expensive and has long waiting times in the West: An Australian patient found an accessible "cure" in China.

OncologyHematology

Patient records Name: Sarah Age: 32 Nationality: Australia Diagnosis: Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), non-germinal center type (non-GCB), CD19 positive, relapsed after autologous stem cell transplantation. Treatment Hospital: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin) In the field of cancer treatment, CAR-T cell therapy is hailed as "living medicine," bringing hope of a cure to patients with relapsed or refractory hemat

View case details →

CASE 03

PATIENT JOURNEY

When CAR-T "Failed": How a Singaporean child found a backup plan in China Patient records

Hematology

Name: Ethan (pseudonym) Age: 8 years old Nationality: Singapore Diagnosis: Relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), CD19-negative relapse after CD19 CAR-T therapy. Treatment Hospital: Shanghai Children's Medical Center In the field of childhood leukemia treatment, CAR-T cell therapy has brought hope to countless families. But when this "living drug" also fails, patients' families face an abyss of near despair. Ethan's story tells how we helped a family find a "backup plan" with

View case details →

Service Process

A clear, coordinated process for efficient cross-border care

01
Pre-Visit Services
Contact us for help organising and translating medical records, planning consultations, and finding suitable hospitals and specialists.
02
Remote Consultations
A remote consultation helps establish an initial approach to diagnosis and treatment, with a cost estimate available within 48 hours.
03
Travel Arrangements
We assist with visa applications, book flights and hotel or apartment accommodation, and arrange airport pick-up, private transport and check-in.
04
Comprehensive Support in China
We accompany you to medical appointments and provide interpreting services, help arrange specialist consultations or surgery, assist with hospital admission and discharge, and help settle medical bills.
05
Post-Visit Services
We assist with notarisation of medical expense documents, airport drop-off, organisation and translation of medical records, remote rehabilitation guidance, and coordination of international referrals.

Next Step

Get a Care Plan
and Cost Estimate.

Tell us about your diagnosis and needs, and our team will help screen the right hospital and explain the next steps.

Email:goldentcm@163.com

Primary immune thrombocytopenic purpura
Treatment in China

About Primary immune thrombocytopenic purpura

Primary immune thrombocytopenic purpura Treatment in China

Recommended Hospitals

Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Southern Medical University Southern Hospital

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Trusted Expertise Across Leading Specialties

Feng Ru

Sun Jing

Zhang Xiaobing

Zhao Weili

Liu Qifa

Li Junmin

Chen Saijuan

Pan Jing

Wang Jianxiang

Zhang Ruidong

Wu Runhui

Zhang Rui

Zhai Xiaowen

Shen Shuhong

See the Next Step Through Patient Journeys

Lower Extremity Arteriosclerosis Obliterans - A Masterpiece for Unblocking the "Silent Killer"

Lymphoma : While CAR-T therapy is prohibitively expensive and has long waiting times in the West: An Australian patient found an accessible "cure" in China.

When CAR-T "Failed": How a Singaporean child found a backup plan in China Patient records

A clear, coordinated process for efficient cross-border care

Pre-Visit Services

Remote Consultations

Travel Arrangements

Comprehensive Support in China

Post-Visit Services

Get a Care Plan
and Cost Estimate.

Get a Care Plan and Estimate

Primary immune thrombocytopenic purpuraTreatment in China

Primary immune thrombocytopenic purpura Treatment in China

Recommended Hospitals

Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Southern Medical University Southern Hospital

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Trusted Expertise Across Leading Specialties

See the Next Step Through Patient Journeys

Lower Extremity Arteriosclerosis Obliterans - A Masterpiece for Unblocking the "Silent Killer"

Lymphoma : While CAR-T therapy is prohibitively expensive and has long waiting times in the West: An Australian patient found an accessible "cure" in China.

When CAR-T "Failed": How a Singaporean child found a backup plan in China Patient records

A clear, coordinated process for efficient cross-border care

Pre-Visit Services

Remote Consultations

Travel Arrangements

Comprehensive Support in China

Post-Visit Services

Get a Care Planand Cost Estimate.

Get a Care Plan and Estimate

Primary immune thrombocytopenic purpura
Treatment in China

Get a Care Plan
and Cost Estimate.